Monopar Therapeutics (NASDAQ:MNPR) Cut to Sell at Wall Street Zen

by · The Markets Daily

Wall Street Zen lowered shares of Monopar Therapeutics (NASDAQ:MNPR – Free Report) from a hold rating to a sell rating in a research note issued to investors on Saturday morning.

A number of other research firms have also recently issued reports on MNPR. Barclays set a $125.00 target price on Monopar Therapeutics and gave the stock an “overweight” rating in a research note on Monday, October 13th. Morgan Stanley initiated coverage on shares of Monopar Therapeutics in a research report on Friday. They set an “overweight” rating and a $115.00 price objective for the company. Leerink Partnrs raised shares of Monopar Therapeutics to a “strong-buy” rating in a research report on Monday, November 10th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Monopar Therapeutics in a research note on Wednesday, September 24th. Finally, Chardan Capital lifted their price target on Monopar Therapeutics from $85.00 to $100.00 and gave the company a “buy” rating in a research note on Sunday, November 9th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Monopar Therapeutics has a consensus rating of “Buy” and a consensus target price of $107.00.

View Our Latest Report on Monopar Therapeutics

Monopar Therapeutics Stock Up 3.2%

Shares of MNPR stock opened at $65.03 on Friday. Monopar Therapeutics has a 12-month low of $24.00 and a 12-month high of $105.00. The firm has a fifty day moving average of $75.64 and a 200-day moving average of $62.66. The firm has a market capitalization of $434.40 million, a price-to-earnings ratio of -18.90 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR – Get Free Report) last posted its earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Research analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current year.

Insider Activity at Monopar Therapeutics

In related news, CFO Quan Anh Vu acquired 1,500 shares of the firm’s stock in a transaction dated Friday, December 26th. The stock was bought at an average price of $69.95 per share, for a total transaction of $104,925.00. Following the acquisition, the chief financial officer directly owned 1,500 shares of the company’s stock, valued at approximately $104,925. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Goldman Sachs Group Inc. acquired a new position in shares of Monopar Therapeutics during the 1st quarter worth approximately $673,000. Jane Street Group LLC bought a new position in shares of Monopar Therapeutics in the first quarter valued at $377,000. AlphaQuest LLC increased its holdings in Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company’s stock worth $64,000 after buying an additional 569 shares during the last quarter. Geode Capital Management LLC increased its holdings in Monopar Therapeutics by 99.7% during the second quarter. Geode Capital Management LLC now owns 96,919 shares of the company’s stock worth $3,468,000 after buying an additional 48,379 shares during the last quarter. Finally, Police & Firemen s Retirement System of New Jersey bought a new stake in Monopar Therapeutics during the second quarter worth $34,000. 1.83% of the stock is owned by institutional investors and hedge funds.

About Monopar Therapeutics

(Get Free Report)

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.

Featured Articles